LEADERS: 5-Year Follow-up

Size: px
Start display at page:

Download "LEADERS: 5-Year Follow-up"

Transcription

1 LEADERS: -Year Follow-up from a Prospective, Randomized Trial of Biolimus A9-eluting Stents with a Biodegradable Polymer vs. Sirolimus-eluting Stents with a Durable Polymer : Final Report of the LEADERS study Presented by P. Serruys at TCT 212 On behalf of the LEADERS investigators EN

2 Biolimus-A9 Eluting Stent Biolimus is a semi-synthetic sirolimus analogue with 1x higher lipophilicity and similar potency as sirolimus. Biolimus is immersed at a concentration of 1.6 g/mm into a biodegradable polymer, polylactic acid, and applied solely to the abluminal stent surface by a fully automated process. Biolimus is co-released with polylactic acid and completely desolves into carbon dioxide and water after a 6-9 months period. The stainless steel stent platform has a strut thickness of 12 m with a quadrature link design.

3 LEADERS all-comers Trial Design Stable and ACS Patients Undergoing PCI Assessor-blind 1:1 Randomisation N=17 Patients 1 European centers BioMatrix Flex () N=8 Cypher Select () N=8 1:3 Randomisation Clinical F/U N=64 Angio F/U N=21 Clinical F/U N=64 Angio F/U N=21 1 o endpoint: MACE: Cardiac death, MI, clinically-indicated TVR (9 mo) 2 o endpoints: Death, CV death, MI, TLR, TVR Stent thrombosis according to ARC Angiographic study: In-stent % diameter stenosis (9 mo) Late loss, binary restenosis DAPT recommended for 12 months

4 Patient Demographics 87 Patients 8 Patients Age in years Male gender 7% 7% Arterial hypertension 74% 73% Diabetes mellitus 26% 23% - insulin-dependent 1% 9% Hypercholesterolemia 6% 68% Family history of CAD 4% 44% Smoking 24% 2% Previous MI 32% 33% Previous PCI 36% 37% - with drug-eluting stent 12% 14% Previous CABG 11% 13%

5 Patient Characteristics 87 Patients 8 Patients Chronic stable angina 4% 44% Acute coronary syndrome % 6% Unstable angina 22% 21% Non-ST-elevation MI 17% 18% ST-elevation MI 16% 17% Left ventricular ejection fraction 6 11% 12% Number of lesions per patient Lesions per patient 1 lesion 63% 69% 2 lesions 29% 22% 3 lesions 7% 8% > 4 lesions 1% 2% De novo lesions 92% 91% Long lesions (>2 mm) 31% 27% Small vessels (RVD 2.7 mm) 68% 67% Off label use 81% 78%

6 Patient Flow - Clinical (N=87) (N=839) (N=832) (N=819) (N=838) (N=833) Randomized (N=1,77) 1-year follow-up (N=1,669; 97.8%) 2-year follow-up (N=1,67; 97.1%) 3-year follow-up (N=1,636; 9.8%) 4-year follow-up (N=1,663; 97.4%) -year follow-up (N=1,647; 96.%) (N=8) (N=83) (N=82) (N=817) (N=82) (N=814) 13 Lost to FU 2 lost to FU and alive 11 lost to FU and vital status unknown 11 withdrew 24 Lost to FU 8 lost to FU and alive 16 lost to FU and vital status unknown 12 withdrew

7 MACE (Cardiac Death, MI and ci-tvr) year RR.88 ( ) P=.38* 12.1% Δ % 2-year RR.83 ( ) P=.1* 1.% Δ % 3-year RR.8 ( ) P=.6* 19.3% Δ % 4-year RR.82 ( ) P=.9* 23.1% Δ % -year RR.83 ( ) P=.71* 26.1 % Δ % P non-inferiority < Number at risk MACE = cardiac death, MI, or clinically-indicated TVR

8 Cardiac Death year RR.78 ( ) P=.42* 2-year RR.79 ( ) P=.36* 3-year RR.81 ( ) P=.34* 4-year RR.88 ( ) P=.2* -year RR.94 ( ) P=.72* % 2.7% 4.%.2% 6.9% Δ.8 Δ.4 Δ.8 Δ 1. Δ.6 8. % 2.1% 3.2% 4.2% 6.1% Number at risk

9 MI year RR 1.27 ( ) P=.26* 2-year RR 1.12 ( ) P=.7* 3-year RR 1.1 ( ) P=.97* 4-year RR.97 (.7-1.3) P=.87* -year RR.96 ( ) P=.79* % 7.3% 9.%.9% 6.4% Δ 1.3 Δ.7 Δ.1 Δ.4 Δ.6 4.6%.7% 7.2% 8.6% % Number at risk

10 QW-MI 6 1-year RR.6 ( ) P=.36* 2-year RR.49 ( ) P=.2* 3-year RR.39 ( ) P=.12* 4-year RR.3 ( ) P=.17* -year RR.49 ( ) P=.98* % 1.% 1.2% 1.6%.8% Δ.3 Δ. Δ.7 Δ 1. Δ.7.%.%.%.9% 1.% Number at risk

11 Non QW-MI year RR 1.38 ( ) P=.1* 2-year RR 1.2 ( ) P=.38* 3-year RR 1.4 ( ) P=.82* 4-year RR 1. ( ) P=.98* -year RR.99 ( ) P=.9* 1 1.4% Δ % 4.9%.9% 6.8% Δ 1. Δ.4 6.4% 9. % 7.8% Δ.1 Δ.1 7.7% 8.9 % Number at risk

12 Clinically-Indicated TVR year RR.82 ( ) P=.3* 7.2% Δ % 2-year RR.8 ( ) P=.34* 3-year RR.8 (.9-1.8) P=.1* 8.9% 11.% Δ 1.2 Δ % 4-year RR.81 ( ) P=.14* 13.6% Δ % 11.2% -year RR.81 (.63-1.) P=.12* 1.% Δ % Number at risk

13 Patient Oriented Composite Endpoint (All-cause Death, Any MI, All Revascularization) Number at risk 1-year RR.84 ( ) P=.11* 21.6% Δ % 2-year RR.83 (.68-1.) P=.* 26.4% Δ % 3-year RR.81 ( ) P=.18* 31.8% Δ % 4-year RR.83 (.7-.98) P=.24* 36.2% Δ.2 31.% POCE = all death, MI, any revascularization (includes adjudicated and non-adjudicated events) -year RR.84 ( ) P=.24* 4.4% Δ.3 3.1%

14 Definite Stent Thrombosis (ARC) year RR.99 ( ) P=.98* 2.% Δ. 2-year RR.9 ( ) P=.73* 2.% 2.2% 3-year RR.78 ( ) P=.43* 4-year RR.62 (.3-1.8) P=.9* 4.% 2.% 2.9% Δ.3 Δ.7 Δ % 2.4% -year RR.6 (.3-1.2) P=.6* 4. % Δ % Number at risk

15 Effect of DAPT Discontinuation. Overall Population P =.62* Patient who d/c DAPT P =.3* P =.2* N=22/87 N=36/8 Y definite ST in LEADERS..3 N=/16 N=6/16 definite ST after DAPT d/c < 12 M N=2/9 N=1/72 definite ST after DAPT d/c > 12 M (Fisher Exact Test)

16 Definite ST (ARC) Landmark 1 Year 6 to 1 year RR.99 (.1-1.9) P=.98* 1 to year RR.26 (.1-.68) P=.3* 4 % 3 2. % 2 2. % 2. % 1.66 % P for interaction=.22

17 Cumulative incidence events (%) Cumulative incidence events (%) Cumulative incid 1 1 able) or triangle (possible) d: d: MACE Days Days since since Procedure Durable/Biodegradable Polymer DES Clinical Events (Corrected KM Estimates) Linked to to ARC Definition ST Definite ST Probable ST Cardiac Death/MI/Ci TVR Cardiac Death/MI Leaders Y: Leaders Y: Event incidence Possible curves, showing events ST related to ST as circle Cardiac (definite), square (probable) Death or triangle (possible) Event incidence curves, showing events related to ST as circle (definite), square (probable) or triangle (possible) Censoring 4 events related 6 to definite, 7 probable 8 and 9 possible 1 ST Censoring 2 events related to definite, probable and possible ST Black: Cardiac Death, Green: Composite of Cardiac Death and MI, Red: MACE Black: Cardiac Death, Green: Composite of Cardiac Death and MI, Red: MACE Days since Procedure Durable Polymer () Days 14 since 1 Procedure Days since Procedure Days since Procedure 4 6 Days Days since since Procedure Days since Procedure Δ 8.2% 2 Biodegradable Polymer () Δ 6.4% Δ 8.7% 1 Δ 7.4% Δ 6.4% Δ 6.% Days since Procedure Days since Procedure

18 Stratified Analysis of Years Favors Favors RR (9%CI) P* Overall 186 (21.7) 216 (2.4).83 (.68 to 1.2).69 Diabetes mellitus ACS Yes 66 (29.6) 6 (29.3) 1.2 (.71 to 1.46).91 No 94 (14.8) 136 (2.6).7 (.4 to.91).7 P for interaction Yes 83 (17.7) 16 (22.4).77 (.8 to 1.3).73 No 77 (19.9) 86 (22.8).86 (.63 to 1.18).3 ST elevation MI.4 Yes 1 (11.1) 32 (22.9).4 (.24 to.83).9 No 14 (2.1) 16 (22.).89 (.71 to 1.11).29 Left anterior descending ns Yes 74 (18.2) 8 (2.4).88 (.64 to 1.2).41 No 86 (19.2) 17 (24.8).76 (.7 to 1.1).6 Multivessel disease ns Yes 44 (21.1) 48 (27.3).7 (.49 to 1.13).16 No 116 (17.9) 144 (21.4).83 (.6 to 1.6).13 De-novo lesions ns Yes 139 (17.6) 16 (21.3).81 (.6 to 1.2).76 No 21 (3.9) 27 (36.).82 (.46 to 1.4).49 Small-vessel disease ns Yes 12 (2.) 131 (23.1).88 (.69 to 1.13).33 No 4 (14.8) 61 (21.8).6 (.44 to.97).33 Long lesions ns Yes 4 (2.6) 63 (28.).72 (. to 1.3).71 No 16 (17.8) 129 (2.7).8 (.66 to 1.1).21 ns ns All p-values are for superiority * Mantel Cox p-value

19 Conclusions Biodegradable polymer maintained non-inferiority and improved long-term clinical outcomes compared to through years (P sup =.71) Biodegradable polymer demonstrated a 74% relative risk reduction in very late definite stent thrombosis (VLST) The benefit of biodegradable polymer emerged in the very late phase and was mainly driven by a lower risk of MACE associated with definite VLST

20 Biolimus A9, BA9, and BioMatrix Flex are trademarks or registered trademarks of Biosensors International group, Ltd. All cited trademarks are the property of their respective owners Not available for sale in the United States and certain other countries. 212 Biosensors International Group, Ltd. All rights reserved

21 All Death year RR.96 ( ) P=.87* 3.3% Δ.1 3.2% 2-year RR.88 (.8-1.3) P=.7* 3-year RR.8 ( ) P=.24*.3% 7.6% Δ 1.4 Δ.6 4.7% 6.2% 4-year RR.9 ( ) P=.48* 1.4% Δ % -year RR.88 ( ) P=.34* 13.7 % Δ % Number at risk

22 Years Separated by Median SYNTAX Score (12) The SYNTAX score has no significant effect on the primary endpoint between and Syntax Score 12 Syntax Score 12 Syntax Score <12 Syntax Score <12 Low Syntax (< 12) vs. -year RR.86 ( ) P=.43* High Syntax ( 12) vs. -year RR.71 (.3-.9) P=.21* 3.3% 22.7% 18.8% 16.4% 1 Interaction p-value:.4 Log rank (low vs. high) p-value: <

23 Definite Years Separated by Median SYNTAX Score (12) is associated with a significant reduction in definite ST in the higher SYNTAX scores Syntax Score 12 Syntax Score 12 Syntax Score <12 Syntax Score <12 Low Syntax (< 12) vs -year RR 1.37 ( ) P=.6* High Syntax ( 12) vs -year RR.38 ( ) P=.1* 6.6% 4 2 Interaction p-value:.6 Log rank (high vs. low) p-value: % 2.4% 1.9%

Antonio Colombo MD on behalf of the SECURITY Investigators

Antonio Colombo MD on behalf of the SECURITY Investigators Second Generation Drug-Eluting Stents Implantation Followed by Six Versus Twelve-Month - Dual Antiplatelet Therapy - The SECURITY Randomized Clinical Trial Antonio Colombo MD on behalf of the SECURITY

More information

Copenhagen University Hospital Rigshospitalet Aarhus University Hospital Skejby Denmark

Copenhagen University Hospital Rigshospitalet Aarhus University Hospital Skejby Denmark Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-elevation myocardial infarction 3 year follow-up of the randomised trial Peter Clemmensen, Henning Kelbæk,

More information

A Post-market Study to Assess the STENTYS Self-exPanding COronary Stent In AcuTe myocardial InfarctiON in Real Life APPOSITION III

A Post-market Study to Assess the STENTYS Self-exPanding COronary Stent In AcuTe myocardial InfarctiON in Real Life APPOSITION III A Post-market Study to Assess the STENTYS Self-exPanding COronary Stent In AcuTe myocardial InfarctiON in Real Life APPOSITION III Gilles Montalescot, MD, PhD Pitié-Salpêtrière Hospital, Paris, France

More information

MEDICAL POLICY No. 91580-R1 DRUG-ELUTING STENTS FOR ISCHEMIC HEART DISEASE

MEDICAL POLICY No. 91580-R1 DRUG-ELUTING STENTS FOR ISCHEMIC HEART DISEASE DRUG-ELUTING STENTS FOR ISCHEMIC HEART DISEASE Effective Date: October 1, 2015 Review Dates: 10/11, 10/12, 10/13, 8/14, 8/15 Date Of Origin: October 12, 2011 Status: Current Summary of Changes Clarifications:

More information

Pooled RESOLUTE Clinical Program

Pooled RESOLUTE Clinical Program The Relationship Between Short and Long-term Antiplatelet Therapy Use and Stent Thrombosis Following Percutaneous Coronary Intervention With the Resolute Zotarolimus-eluting Stent Pooled RESOLUTE Clinical

More information

Intracoronary Stenting and. Robert A. Byrne, Julinda Mehilli, Salvatore Cassese, Franz-Josef Neumann, Susanne Pinieck, Tomohisa Tada,

Intracoronary Stenting and. Robert A. Byrne, Julinda Mehilli, Salvatore Cassese, Franz-Josef Neumann, Susanne Pinieck, Tomohisa Tada, Prospective, Randomized Trial of Paclitaxel-Eluting Balloon versus Paclitaxel-Eluting Stent versus Balloon Angioplasty for Treatment of Coronary Restenosis in Limus- Eluting Stents Intracoronary Stenting

More information

PRECOMBAT Trial. Seung-Whan Lee, MD, PhD On behalf of the PRECOMBAT Investigators

PRECOMBAT Trial. Seung-Whan Lee, MD, PhD On behalf of the PRECOMBAT Investigators Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease PRECOMBAT Trial Seung-Whan Lee, MD, PhD On behalf

More information

Cilostazol versus Clopidogrel after Coronary Stenting

Cilostazol versus Clopidogrel after Coronary Stenting Cilostazol versus Clopidogrel after Coronary Stenting Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine Seoul, Korea AMC, 2004 Background

More information

University of Ulsan College of Medicine, Asan Medical Center on behalf of the REAL-LATE and the ZEST-LATE trial

University of Ulsan College of Medicine, Asan Medical Center on behalf of the REAL-LATE and the ZEST-LATE trial Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation A Pooled Analysis of the REAL-LATE and the ZEST-LATE Trial Seung-Jung Park MD PhD Seung-Jung Park, MD, PhD, University of Ulsan

More information

OPTIMIZE: A Prospective, Randomized Trial of 3 Months Versus 12 Months of Dual Antiplatelet Therapy with the Endeavor Zotarolimus-Eluting Stent

OPTIMIZE: A Prospective, Randomized Trial of 3 Months Versus 12 Months of Dual Antiplatelet Therapy with the Endeavor Zotarolimus-Eluting Stent Main Arena III - Plenary Sessions XVI Late Breaking Clinical Trials III - Featured Trial of the Day: OPTIMIZE: A Prospective, Randomized Trial of 3 Months Versus 12 Months of Dual Antiplatelet Therapy

More information

DUAL ANTIPLATELET THERAPY. Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania

DUAL ANTIPLATELET THERAPY. Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania DUAL ANTIPLATELET THERAPY Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania DUAL ANTIPLATELET THERAPY (DAPT) Dual antiplatelet regimen

More information

OCT STEMI: OCT guidance during stent implantation

OCT STEMI: OCT guidance during stent implantation OCT STEMI: OCT guidance during stent implantation in primary PCI. A Randomized Multicenter study with 9-month optical coherence tomography follow-up Červinka P 1,2, Kala P 3, Jakl M 2,4, Kaňovský J 3,

More information

Clinical Research Intracoronary Stenting with Crushing in Coronary Artery Bifurcation Lesions: Initial Results and Medium-Term Follow Up

Clinical Research Intracoronary Stenting with Crushing in Coronary Artery Bifurcation Lesions: Initial Results and Medium-Term Follow Up Hellenic J Cardiol 45: 379-383, 2004 Clinical Research Intracoronary Stenting with Crushing in Coronary Artery Bifurcation Lesions: Initial Results and Medium-Term Follow Up PETROS S. DARDAS, DIMITRIS

More information

The BASE-ACS Trial. A Randomized Comparison of a TITAN-2 BAS with XIENCE-V- EES Stent in Acute Coronary Syndrome. 18 months Follow-up results

The BASE-ACS Trial. A Randomized Comparison of a TITAN-2 BAS with XIENCE-V- EES Stent in Acute Coronary Syndrome. 18 months Follow-up results The BASE-ACS Trial A Randomized Comparison of a TITAN-2 BAS with XIENCE-V- EES Stent in Acute Coronary Syndrome 18 months Follow-up results Pasi Karjalainen, MD, PhD, adjunct Professor on behalf of the

More information

The Minvasys Amazonia Pax & Nile Pax Polymer Free Paclitaxel Eluting Stent Program

The Minvasys Amazonia Pax & Nile Pax Polymer Free Paclitaxel Eluting Stent Program The Minvasys Amazonia Pax & Nile Pax Polymer Free Paclitaxel Eluting Stent Program Jean Fajadet, MD, FESC Clinique Pasteur - Toulouse - France Disclosure statement Nothing to disclose Dedicated Delivery

More information

The Pantera Lux Paclitaxel DEB Device Description and Clinical Studies. Christoph Hehrlein, University Clinic Freiburg i.br.

The Pantera Lux Paclitaxel DEB Device Description and Clinical Studies. Christoph Hehrlein, University Clinic Freiburg i.br. The Pantera Lux Paclitaxel DEB Device Description and Clinical Studies Christoph Hehrlein, University Clinic Freiburg i.br. Germany Disclosure Statement of Financial Interest Within the past 12 months,

More information

Is Stenting or Coronary Artery By-pass Grafting the Better Treatment for This Patient?

Is Stenting or Coronary Artery By-pass Grafting the Better Treatment for This Patient? Is Stenting or Coronary Artery By-pass Grafting the Better Treatment for This Patient? --- NIRS-IVUS TVC Imaging Adds Additional Information for the Heart Team Dr. Luis Tami Memorial Regional Hospital

More information

06 Validation of risk prediction model

06 Validation of risk prediction model HA Territory-wide PCI Audit 2003-06 06 Validation of risk prediction model PCI Audit Working Group Central Committee (Cardiac Services) HA Convention 2007 Background Participants: All HA hospitals via

More information

Clinical Programs. Medtronic Coronary Stent Systems. driver BMS

Clinical Programs. Medtronic Coronary Stent Systems. driver BMS Clinical Programs Medtronic Coronary Stent Systems Endeavor DES driver BMS July 2010 Contents Overview of Clinical Programs... 2 Drug-Eluting Stents ENDEAVOR I*... 4 ENDEAVOR II*... 6 ENDEAVOR II Continued

More information

Déjeuner/Repas Débat ABBOTT «Docteur, je veux un stent qui se dissout» ABSORB,la révolu@on oui, mais chez quel pa@ent? Les dernières données ABSORB

Déjeuner/Repas Débat ABBOTT «Docteur, je veux un stent qui se dissout» ABSORB,la révolu@on oui, mais chez quel pa@ent? Les dernières données ABSORB Déjeuner/Repas Débat ABBOTT «Docteur, je veux un stent qui se dissout» ABSORB,la révolu@on oui, mais chez quel pa@ent? Les dernières données ABSORB Didier Carrié CHU Toulouse APPAC 4 Juin 2014 Aucun conflit

More information

Duration of Dual Antiplatelet Therapy After Coronary Stenting

Duration of Dual Antiplatelet Therapy After Coronary Stenting Duration of Dual Antiplatelet Therapy After Coronary Stenting C. DEAN KATSAMAKIS, DO, FACC, FSCAI INTERVENTIONAL CARDIOLOGIST ADVOCATE LUTHERAN GENERAL HOSPITAL INTRODUCTION Coronary artery stents are

More information

Prognostic impact of uric acid in patients with stable coronary artery disease

Prognostic impact of uric acid in patients with stable coronary artery disease Prognostic impact of uric acid in patients with stable coronary artery disease Gjin Ndrepepa, Siegmund Braun, Martin Hadamitzky, Massimiliano Fusaro, Hans-Ullrich Haase, Kathrin A. Birkmeier, Albert Schomig,

More information

Pantera Lux Device Description and Overview of Clinical Data

Pantera Lux Device Description and Overview of Clinical Data Pantera Lux Device Description and Overview of Clinical Data Ralph Tölg, MD Herzzentrum Segeberger Kliniken GmbH Bad Segeberg, Germany Disclosure Statement of Financial Interest Within the past 12 months,

More information

Early healing after treatment of coronary lesions by everolimus, or biolimus eluting bioresorbable polymer stents

Early healing after treatment of coronary lesions by everolimus, or biolimus eluting bioresorbable polymer stents Early healing after treatment of coronary lesions by everolimus, or biolimus eluting bioresorbable polymer stents One-month results of the study Ida Riise Balleby 1, Trine Krejberg Ørhøj 1, Christian Juhl

More information

Do método diagnóstico ao terapêutico: a História da Hemodinâmica e da Cardiologia Intervencionista, em 15 minutos. Eulógio E Martinez

Do método diagnóstico ao terapêutico: a História da Hemodinâmica e da Cardiologia Intervencionista, em 15 minutos. Eulógio E Martinez Do método diagnóstico ao terapêutico: a História da Hemodinâmica e da Cardiologia Intervencionista, em 15 minutos Eulógio E Martinez IVUS vs luminologia Positivo Negativo estenose TCE oclusão CD sístole

More information

EXAMINATION trial. Manel Sabaté Hospital Clínic, Barcelona (On behalf of the Examination Investigators)

EXAMINATION trial. Manel Sabaté Hospital Clínic, Barcelona (On behalf of the Examination Investigators) EXAMINATION trial Manel Sabaté Hospital Clínic, Barcelona (On behalf of the Examination Investigators) EXAMINATION trial Background and Rationale (I) Acute coronary syndromes repeatedly appear as independent

More information

Presenter: Marco Valgimigli, MD PhD, FESC Erasmus MC, Thoraxcenter Rotterdam The Netherlands

Presenter: Marco Valgimigli, MD PhD, FESC Erasmus MC, Thoraxcenter Rotterdam The Netherlands Comparing zotarolimus-eluting and bare-metal stent efficacy in selected high bleeding risk patients treated with a short dual antiplatelet therapy duration. A pre-specified analysis from the The Zotarolimuseluting

More information

Drug-Eluting Balloons. Klaus Bonaventura Department of Cardiology and Angiology Heart Thorax Vascular Center, Klinikum Ernst von Bergmann, Potsdam

Drug-Eluting Balloons. Klaus Bonaventura Department of Cardiology and Angiology Heart Thorax Vascular Center, Klinikum Ernst von Bergmann, Potsdam Drug-Eluting Balloons Klaus Bonaventura Department of Cardiology and Angiology Heart Thorax Vascular Center, Klinikum Ernst von Bergmann, Potsdam Potential conflicts of interest Speaker s name: Klaus Bonaventura

More information

Majestic Trial 12 Month Results

Majestic Trial 12 Month Results Majestic Trial 12 Month Results S.Müller-Hülsbeck, MD, EBIR, FCIRSE, FICA ACADEMIC HOSPITALS Flensburg of Kiel University Ev.-Luth. Diakonissenanstalt zu Flensburg Knuthstraße 1, 24939 FLENSBURG Dept.

More information

Ostial LAD: Single stent approach is the best. Antonio A. Pocoví, MD, FSCAI, MTSAC, Advisory Council Member, CACI

Ostial LAD: Single stent approach is the best. Antonio A. Pocoví, MD, FSCAI, MTSAC, Advisory Council Member, CACI Ostial LAD: Single stent approach is the best Antonio A. Pocoví, MD, FSCAI, MTSAC, Advisory Council Member, CACI Chair, Interventional Cardiology Sanatorio San Lucas Instituto Alexander Fleming Buenos

More information

Dual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute

Dual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute Dual Antiplatelet Therapy Stephen Monroe, MD FACC Chattanooga Heart Institute Scope of Talk Identify the antiplatelet drugs and their mechanisms of action Review dual antiplatelet therapy in: The medical

More information

Health Related Quality of Life and U.S. Economic Outcomes of PCI with Drug-Eluting Stents vs. Bypass Surgery: 1-Year Results from the SYNTAX Trial

Health Related Quality of Life and U.S. Economic Outcomes of PCI with Drug-Eluting Stents vs. Bypass Surgery: 1-Year Results from the SYNTAX Trial Health Related Quality of Life and U.S. Economic Outcomes of PCI with Drug-Eluting Stents vs. Bypass Surgery: 1-Year Results from the SYNTAX Trial David J. Cohen, Tara A. Lavelle, Patrick W. Serruys, Friedrich

More information

Repeat Coronary Revascularization Procedures after Successful Bare-Metal or Drug-Eluting Stent Implantation

Repeat Coronary Revascularization Procedures after Successful Bare-Metal or Drug-Eluting Stent Implantation Original Contribution Repeat Coronary Revascularization Procedures after Successful Bare-Metal or Drug-Eluting Stent Implantation Cynthia A. Yock, MS, J. Michael Isbill, MS, Spencer B. King III, MD, Mark

More information

PCI vs. CABG for Left Main Disease

PCI vs. CABG for Left Main Disease The EXCEL Ti Trial Design, Status, t and Timelines Gregg W. Stone, MD Columbia University Medical Center NewYork-Presbyterian Hospital Cardiovascular Research Foundation PCI vs. CABG for Left Main Disease

More information

Main Effect of Screening for Coronary Artery Disease Using CT

Main Effect of Screening for Coronary Artery Disease Using CT Main Effect of Screening for Coronary Artery Disease Using CT Angiography on Mortality and Cardiac Events in High risk Patients with Diabetes: The FACTOR-64 Randomized Clinical Trial Joseph B. Muhlestein,

More information

FFR CT : Clinical studies

FFR CT : Clinical studies FFR CT : Clinical studies Bjarne Nørgaard Department Cardiology B Aarhus University Hospital Skejby, Denmark Disclosures: Research grants: Edwards and Siemens Coronary CTA: High diagnostic sensitivity

More information

BRIGHT Trial. Bivalirudin versus Heparin and Heparin plus Tirofiban in Patients with AMI Undergoing PCI. Thirty-Day and One-Year Outcomes of the

BRIGHT Trial. Bivalirudin versus Heparin and Heparin plus Tirofiban in Patients with AMI Undergoing PCI. Thirty-Day and One-Year Outcomes of the Bivalirudin versus Heparin and Heparin plus Tirofiban in Patients with AMI Undergoing PCI Thirty-Day and One-Year Outcomes of the BRIGHT Trial Yaling Han, MD, FACC On behalf of the BRIGHT investigators

More information

Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease

Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease Home SVCC Area: English - Español - Português Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease Martial G. Bourassa, MD Research Center, Montreal Heart Institute, Montreal, Quebec,

More information

ESC PCI Guidelines: / Sigmund Silber et al. 1

ESC PCI Guidelines: / Sigmund Silber et al. 1 For the first time! ESC PCI Guidelines: / Sigmund Silber et al. 1 in 2002: 649.332 in 2002: 541.964 ESC PCI Guidelines: Introduction and Definitions / Sigmund Silber et al. 2 ESC PCI Guidelines: Introduction

More information

Review Article CORONARY STENTS - PAST, PRESENT AND FUTURE.

Review Article CORONARY STENTS - PAST, PRESENT AND FUTURE. Review Article CORONARY STENTS - PAST, PRESENT AND FUTURE. VV JAIN*, S YELWATKAR**, OP GUPTA*** Introduction The advent of period of angioplasty has revolutionized the practice of interventional cardiology.

More information

Coronary Bifurcation Treatment: Update from the European Bifurcation Club. Remo Albiero, MD Ist. Clinico S. Rocco Brescia (Italy)

Coronary Bifurcation Treatment: Update from the European Bifurcation Club. Remo Albiero, MD Ist. Clinico S. Rocco Brescia (Italy) Coronary Bifurcation Treatment: Update from the European Bifurcation Club Remo Albiero, MD Ist. Clinico S. Rocco Brescia (Italy) Disclosure Statement of Financial Interest Within the past 12 months, I

More information

Drug-Eluting Coronary Stents. Paul Montero PGY-II University of Colorado Health Sciences Center Surgical Grand Rounds Resident Debate

Drug-Eluting Coronary Stents. Paul Montero PGY-II University of Colorado Health Sciences Center Surgical Grand Rounds Resident Debate Drug-Eluting Coronary Stents Paul Montero PGY-II University of Colorado Health Sciences Center Surgical Grand Rounds Resident Debate Outline Coronary Artery Disease Evolution of Percutaneous Coronary Intervention

More information

Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation (ISAR-TRIPLE Trial)

Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation (ISAR-TRIPLE Trial) Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation (ISAR-TRIPLE Trial) Katrin A. Fiedler, Michael Maeng, Julinda Mehilli, Stefanie Schulz, Robert

More information

Coronary Artery Bypass Graft Surgery vs Percutaneous Interventions in Coronary Revascularization A Systematic Review

Coronary Artery Bypass Graft Surgery vs Percutaneous Interventions in Coronary Revascularization A Systematic Review Clinical Review & Education Review Coronary Artery Bypass Graft Surgery vs ercutaneous Interventions in Coronary Revascularization A Systematic Review Saswata Deb, MD; Harindra C. Wijeysundera, MD; Dennis

More information

HA Territory-wide PCI Audit 2003-05

HA Territory-wide PCI Audit 2003-05 HA Territory-wide PCI Audit 23-5 5 PCI Audit Working Group Central Committee (Cardiac Services) HA Convention 26 Percutaneous Coronary Intervention Background HA AP target 2/3, coordinated by PCI Working

More information

Advances in Stent Technology

Advances in Stent Technology Nurse/Technologist Symposium Advances in Stent Technology Antonietta Tolentino, CCRN, MSN, ANP-C Adult Nurse Practitioner, Cardiac Catheterization Laboratory The Zena and Michael A. Weiner Cardiovascular

More information

Description of problem Description of proposed amendment Justification for amendment ERG response

Description of problem Description of proposed amendment Justification for amendment ERG response KEY INACCURACIES Issue 1 Distinguishing between groups of STEMI patients Key issue throughout the report The ERG distinguishes between groups of STEMI patients defining four patient groups: STEMI without

More information

GUIDELINES ON MEDICAL DEVICES EVALUATION OF CLINICAL DATA - A GUIDE FOR MANUFACTURERS AND NOTIFIED BODIES -

GUIDELINES ON MEDICAL DEVICES EVALUATION OF CLINICAL DATA - A GUIDE FOR MANUFACTURERS AND NOTIFIED BODIES - EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Cosmetics and Medical Devices MEDDEV 2.7.1 Appendix 1 December 2008 GUIDELINES ON MEDICAL DEVICES EVALUATION OF CLINICAL DATA

More information

Antiplatelet and Antithrombotics From clinical trials to guidelines

Antiplatelet and Antithrombotics From clinical trials to guidelines Antiplatelet and Antithrombotics From clinical trials to guidelines Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University Preisedent of EGYBAC Chairman of WGLVR One of the big stories

More information

Appropriate Use: Big Brother is Watching. Jason H. Rogers, MD Director, Interventional Cardiology UC Davis Medical Center

Appropriate Use: Big Brother is Watching. Jason H. Rogers, MD Director, Interventional Cardiology UC Davis Medical Center Appropriate Use: Big Brother is Watching Jason H. Rogers, MD Director, Interventional Cardiology UC Davis Medical Center Disclosures Consultant Boston Scientific, Medtronic, Middle Peak Medical, Millipede,

More information

Clinical Results of Unprotected Left Main Coronary Stenting

Clinical Results of Unprotected Left Main Coronary Stenting Original Articles IMAJ VOL 11 MARCH 2009 Clinical Results of Unprotected Left Main Coronary Stenting Itsik Ben-Dor MD, Hana Vaknin-Assa MD, Eli Lev MD, David Brosh MD, Shmuel Fuchs MD, Abid Assali MD and

More information

Rivaroxaban for acute coronary syndromes

Rivaroxaban for acute coronary syndromes Northern Treatment Advisory Group Rivaroxaban for acute coronary syndromes Lead author: Nancy Kane Regional Drug & Therapeutics Centre (Newcastle) May 2014 2014 Summary Current long-term management following

More information

Controversies in the use & implementation of drug-eluting stent technology

Controversies in the use & implementation of drug-eluting stent technology Review Article Indian J Med Res 136, December 2012, pp 926-941 Controversies in the use & implementation of drug-eluting stent technology Brandon K. Itagaki * & Somjot S. Brar *,** * Regional Cardiac Cath

More information

Polymer-Based, Paclitaxel-Eluting TAXUS Liberté Stent in De Novo Lesions: The Pivotal TAXUS ATLAS Trial

Polymer-Based, Paclitaxel-Eluting TAXUS Liberté Stent in De Novo Lesions: The Pivotal TAXUS ATLAS Trial Polymer-Based, Paclitaxel-Eluting Stent in De Novo Lesions: The Pivotal TAXUS ATLAS Trial Mark A. Turco, John A. Ormiston, Jeffrey J. Popma, Lazar Mandinov, Charles D. O'Shaughnessy, Tift Mann, Thomas

More information

Editorial. Adult Cardiology - Meta-analysis

Editorial. Adult Cardiology - Meta-analysis Editorial Adult Cardiology - Meta-analysis Simple Versus Complex Bifurcation Stenting Strategies A Meta Analysis of Randomized Controlled Trials in the Drug Eluting Stent Era Ana Beatriz R. Medrano, MD

More information

Addendum to Clinical Review for NDA 22-512

Addendum to Clinical Review for NDA 22-512 Addendum to Clinical Review for DA 22-512 Drug: Sponsor: Indication: Division: Reviewers: dabigatran (Pradaxa) Boehringer Ingelheim Prevention of stroke and systemic embolism in atrial fibrillation Division

More information

Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes (Review)

Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes (Review) Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes (Review) Greenhalgh J, Hockenhull J, Rao N, Dundar Y, Dickson RC, Bagust A This is a reprint of a Cochrane review, prepared

More information

Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Recommendations of the European Society of Cardiology Updated version December 2002 Task Force on management

More information

Using Clinical Registries to Create Evidence-based Health Care Policy : Experiences from Ontario, Canada

Using Clinical Registries to Create Evidence-based Health Care Policy : Experiences from Ontario, Canada Using Clinical Registries to Create Evidence-based Health Care Policy : Experiences from Ontario, Canada April 2009 Jack V. Tu, MD PhD FRCPC CANADA RESEARCH CHAIR IN HEALTH SERVICES RESEARCH Institute

More information

WOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION. Van Crisco, MD, FACC, FSCAI First Coast

WOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION. Van Crisco, MD, FACC, FSCAI First Coast WOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION Van Crisco, MD, FACC, FSCAI First Coast Conflicts of Interest I have been a paid consultant and speaker for AstraZeneca, makers of

More information

Dual Antiplatelet Therapy Beyond One Year in Patients Receiving Coronary Stents for Treatment of Acute Coronary Syndromes

Dual Antiplatelet Therapy Beyond One Year in Patients Receiving Coronary Stents for Treatment of Acute Coronary Syndromes Dual Antiplatelet Therapy Beyond One Year in Patients Receiving Coronary Stents for Treatment of Acute Coronary Syndromes Robert W. Yeh, Dean J. Kereiakes, P. Gabriel Steg, Stephan Windecker, Michael J.

More information

FULL COVERAGE FOR PREVENTIVE MEDICATIONS AFTER MYOCARDIAL INFARCTION IMPACT ON RACIAL AND ETHNIC DISPARITIES

FULL COVERAGE FOR PREVENTIVE MEDICATIONS AFTER MYOCARDIAL INFARCTION IMPACT ON RACIAL AND ETHNIC DISPARITIES FULL COVERAGE FOR PREVENTIVE MEDICATIONS AFTER MYOCARDIAL INFARCTION IMPACT ON RACIAL AND ETHNIC DISPARITIES Niteesh K. Choudhry, MD, PhD Harvard Medical School Division of Pharmacoepidemiology and Pharmacoeconomics

More information

on behalf of the AUGMENT-HF Investigators

on behalf of the AUGMENT-HF Investigators One Year Follow-Up Results from AUGMENT-HF: A Multicenter Randomized Controlled Clinical Trial of the Efficacy of Left Ventricular Augmentation with Algisyl-LVR in the Treatment of Heart Failure* Douglas

More information

A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease A Report of the

More information

The Bioresorbable Vascular Stent Dr Albert Ko

The Bioresorbable Vascular Stent Dr Albert Ko The Bioresorbable Vascular Stent Dr Albert Ko Dr Albert Ko MB BS, FRACP, FCSANZ Interventional/General Cardiologist Ascot Cardiology Symposium 2013 Treatment Goals for Coronary Artery Disease Relieve of

More information

None. Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management. 76 year old male LINGO 1/5/2015

None. Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management. 76 year old male LINGO 1/5/2015 Financial Disclosure Information Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management Robert D. McBane, M.D. Division of Cardiology Mayo Clinic Rochester Dual Antiplatelet

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Cardiovascular disease has become a dominant cause of

Cardiovascular disease has become a dominant cause of Abstract Immediate and Six-month Clinical Outcome of Percutaneous Coronary Intervention in a Tertiary Hospital in the Sultanate of Oman Panduranga Prashanth, Mohamed Mukhaini, Abdulla A. Riyami, Kadhim

More information

Transcatheter Cardiovascular Therapeutics 19 th Annual Scientific Symposium October 20-25, 2007

Transcatheter Cardiovascular Therapeutics 19 th Annual Scientific Symposium October 20-25, 2007 Comparative Late Risk of Death, Myocardial Infarction, and Stent Thrombosis for Bare-Metal and Drug-Eluting Stents: A Landmark Analysis from the STENT Registry Charles Simonton MD, Bruce Brodie MD, Barrett

More information

Preoperative Cardiac Stents Perioperative Management. Mark A. Taylor, MD Department of Anesthesia

Preoperative Cardiac Stents Perioperative Management. Mark A. Taylor, MD Department of Anesthesia Preoperative Cardiac Stents Perioperative Management Mark A. Taylor, MD Department of Anesthesia Revasc prior to NCS If it offered long term benefit-- --made sense to do it 1-22 vessel CAD by angiogram,

More information

Guidance on the use of coronary artery stents

Guidance on the use of coronary artery stents NHS National Institute for Clinical Excellence Guidance on the use of coronary artery stents Technology Appraisal 71 October 2003 Technology Appraisal Guidance 71 Guidance on the use of coronary artery

More information

CARDIAC RISKS OF NON CARDIAC SURGERY

CARDIAC RISKS OF NON CARDIAC SURGERY CARDIAC RISKS OF NON CARDIAC SURGERY N E W S T U D I E S & N E W G U I D E L I N E S W. B. C A L H O U N, M D, F A C C 2014 ACC/AHA Guideline on perioperative cardiovascular evaluation and management

More information

Status of Drug-Eluting Coronary Stents

Status of Drug-Eluting Coronary Stents Status of Drug-Eluting Coronary Stents EVOLUTION OF PERCUTANEOUS CORONARY INTERVENTIONAL TECHNOLOGIES The introduction of percutaneous transluminal coronary angioplasty (PTCA) in the late1970s provided

More information

Antiaggreganti. STEMI : cosa c è di nuovo? Heartline 2015. Genova 13 14 Novembre 2015

Antiaggreganti. STEMI : cosa c è di nuovo? Heartline 2015. Genova 13 14 Novembre 2015 Heartline 2015 Genova 13 14 Novembre 2015 STEMI : cosa c è di nuovo? Antiaggreganti Luigi Oltrona Visconti Divisione di Cardiologia IRCCS Fondazione Policlinico S. Matteo Pavia STEMI : cosa c è di nuovo?

More information

Cardiac Rehabilitation The Best Medicine for Your CAD Patients. James A. Stone

Cardiac Rehabilitation The Best Medicine for Your CAD Patients. James A. Stone James A. Stone BPHE, BA, MSc, MD, PhD, FRCPC, FAACVPR, FACC Clinical Professor of Medicine, University of Calgary Total Cardiology, Calgary Acknowledgements and Disclosures Acknowledgements Jacques Genest

More information

POST STENTING DUAL ANTIPLATELET THERAPY DURATION J BAUCUM MD FACC CAROLINA CARDIOLOGY GHS

POST STENTING DUAL ANTIPLATELET THERAPY DURATION J BAUCUM MD FACC CAROLINA CARDIOLOGY GHS POST STENTING DUAL ANTIPLATELET THERAPY DURATION J BAUCUM MD FACC CAROLINA CARDIOLOGY GHS Post Stenting Dual Antiplatelet Therapy When can I stop it? Intracoronary stenting is a frequent intervention for

More information

Novel Trial Designs in T2D to Satisfy Regulatory Requirements for CV Safety

Novel Trial Designs in T2D to Satisfy Regulatory Requirements for CV Safety Novel Trial Designs in T2D to Satisfy Regulatory Requirements for CV Safety Anders Svensson MD, PhD Head of Global Clinical Development Metabolism, F Hoffmann LaRoche Ltd. Basel, Switzerland Overview of

More information

Perspectives on the Selection and Duration of Dual Antiplatelet Therapy

Perspectives on the Selection and Duration of Dual Antiplatelet Therapy Perspectives on the Selection and Duration of Dual Antiplatelet Therapy Dominick J. Angiolillo, MD, PhD, FACC, FESC, FSCAI Director of Cardiovascular Research Associate Professor of Medicine University

More information

Drug Eluting Stents: Past, Future & Dual Anti-Platelet Therapy When is Stopping Safe

Drug Eluting Stents: Past, Future & Dual Anti-Platelet Therapy When is Stopping Safe Disclosure Statement of Financial Interest Drug Eluting Stents: Past, Future & Dual Anti-Platelet Therapy When is Stopping Safe Louis A. Cannon, MD, FACC, FSCAI, FACP Program Director, Heart & Vascular

More information

Impact of Massachusetts Health Care Reform on Racial, Ethnic and Socioeconomic Disparities in Cardiovascular Care

Impact of Massachusetts Health Care Reform on Racial, Ethnic and Socioeconomic Disparities in Cardiovascular Care Impact of Massachusetts Health Care Reform on Racial, Ethnic and Socioeconomic Disparities in Cardiovascular Care Michelle A. Albert MD MPH Treacy S. Silbaugh B.S, John Z. Ayanian MD MPP, Ann Lovett RN

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR DISEASE PREVENTION

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR DISEASE PREVENTION European Medicines Agency Pre-Authorisation Evaluation of Medicines for Human Use London, 25 September 2008 Doc. Ref. EMEA/CHMP/EWP/311890/2007 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE

More information

How can registries contribute to guidelines? Nicolas DANCHIN, HEGP, Paris

How can registries contribute to guidelines? Nicolas DANCHIN, HEGP, Paris How can registries contribute to guidelines? Nicolas DANCHIN, HEGP, Paris Pros and cons of registers Prospective randomised trials constitute the cornerstone of "evidence-based" medicine, and they therefore

More information

Is There A LIfe for DES after discontinuation of Clopidogrel

Is There A LIfe for DES after discontinuation of Clopidogrel Chicago 2014 Is There A LIfe for DES after discontinuation of Clopidogrel Six-month versus 24-month dual antiplatelet therapy after implantation of drug eluting stents in patients non-resistant to aspirin:

More information

Primary Prevention of Cardiovascular Disease with a Mediterranean diet

Primary Prevention of Cardiovascular Disease with a Mediterranean diet Primary Prevention of Cardiovascular Disease with a Mediterranean diet Alejandro Vicente Carrillo, Brynja Ingadottir, Anne Fältström, Evelyn Lundin, Micaela Tjäderborn GROUP 2 Background The traditional

More information

PIHRATE Trial. Polish-Italian-Hungarian Randomized ThrombEctomy Trial. Dariusz Dudek MD, PhD. On behalf PIHRATE investigators

PIHRATE Trial. Polish-Italian-Hungarian Randomized ThrombEctomy Trial. Dariusz Dudek MD, PhD. On behalf PIHRATE investigators Polish-Italian-Hungarian Randomized ThrombEctomy Trial PIHRATE Trial On behalf PIHRATE investigators Dariusz Dudek MD, PhD Institute of Cardiology, Krakow, Poland Impact of distal embolization Distal embolization

More information

Getting smart about dyspnea and life saving drug therapy in ACS patients. Kobi George Kaplan Medical Center Rehovot

Getting smart about dyspnea and life saving drug therapy in ACS patients. Kobi George Kaplan Medical Center Rehovot Getting smart about dyspnea and life saving drug therapy in ACS patients Kobi George Kaplan Medical Center Rehovot 78 year old female Case description Presented with resting chest pain and dyspnea Co morbidities:

More information

Impact of Drug-Eluting Stents Among Insulin-Treated Diabetic Patients

Impact of Drug-Eluting Stents Among Insulin-Treated Diabetic Patients JACC: CARDIOVASCULAR INTERVENTIONS VOL. 1, NO. 2, 2008 2008 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/08/$34.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2008.02.005 Impact of

More information

JUL 2 2008. Ms. Kendra Basler Regulatory Affairs Associate Abbott Vascular Cardiac Therapies 3200 Lakeside Drive Santa Clara, CA 95054-2807

JUL 2 2008. Ms. Kendra Basler Regulatory Affairs Associate Abbott Vascular Cardiac Therapies 3200 Lakeside Drive Santa Clara, CA 95054-2807 DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service JUL 2 2008 Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 Ms. Kendra Basler Regulatory Affairs Associate Abbott Vascular

More information

NIHI Big Data in Healthcare Research Case Study

NIHI Big Data in Healthcare Research Case Study NIHI Big Data in Healthcare Research Case Study Professor Rob Doughty Heart Foundation Chair of Heart Health National Institute for Health Innovation and the Dept of Medicine, University of Auckland &

More information

OPINION OPtical frequency domain imaging vs. INtravascular ultrasound in percutaneous coronary InterventiON

OPINION OPtical frequency domain imaging vs. INtravascular ultrasound in percutaneous coronary InterventiON OPINION OPtical frequency domain imaging vs. INtravascular ultrasound in percutaneous coronary InterventiON - Baseline preliminary results - Takashi Akasaka, MD, PhD, FESC Wakayama Medical University,

More information

For the NXT Investigators

For the NXT Investigators Diagnostic performance of non-invasive fractional flow reserve derived from coronary CT angiography in suspected coronary artery disease: The NXT trial Bjarne L. Nørgaard, Jonathon Leipsic, Sara Gaur,

More information

CORONARY ARTERY BYPASS GRAFTS, STENTS, AND EXTRACORONARY CARDIAC DZ. Charles White MD

CORONARY ARTERY BYPASS GRAFTS, STENTS, AND EXTRACORONARY CARDIAC DZ. Charles White MD CORONARY ARTERY BYPASS GRAFTS, STENTS, AND EXTRACORONARY CARDIAC DZ Charles White MD Director of Thoracic Imaging Department of Radiology University of Maryland CORONARY ARTERY BYPASS GRAFTS First performed

More information

Understanding Coronary Artery Disease, Cardiac Catheterization, and Treatment Options. A Guide for Patients

Understanding Coronary Artery Disease, Cardiac Catheterization, and Treatment Options. A Guide for Patients Understanding Coronary Artery Disease, Cardiac Catheterization, and Treatment Options A Guide for Patients Coronary Artery Disease If you or a member of your family has been diagnosed with coronary artery

More information

Perioperative Cardiac Evaluation

Perioperative Cardiac Evaluation Perioperative Cardiac Evaluation Caroline McKillop Advisor: Dr. Tam Psenka 10-3-2007 Importance of Cardiac Guidelines -Used multiple times every day -Patient Safety -Part of Surgical Care Improvement Project

More information

Objectives. Preoperative Cardiac Risk Stratification for Noncardiac Surgery. History

Objectives. Preoperative Cardiac Risk Stratification for Noncardiac Surgery. History Preoperative Cardiac Risk Stratification for Noncardiac Surgery Kimberly Boddicker, MD FACC Essentia Health Heart and Vascular Center 27 th Heart and Vascular Conference May 13, 2011 Objectives Summarize

More information

Tips for surviving the analysis of survival data. Philip Twumasi-Ankrah, PhD

Tips for surviving the analysis of survival data. Philip Twumasi-Ankrah, PhD Tips for surviving the analysis of survival data Philip Twumasi-Ankrah, PhD Big picture In medical research and many other areas of research, we often confront continuous, ordinal or dichotomous outcomes

More information

έΰζβν αππ έκυ,νσϊίία κν1γν πλδζέκυνβί1γ π ηία δεόμνκαλ δκζόΰκμ, θν δ υγυθ άμνγνκαλ /εάμ ΚζδθδεάμΝ υλωεζδθδεάμν

έΰζβν αππ έκυ,νσϊίία κν1γν πλδζέκυνβί1γ π ηία δεόμνκαλ δκζόΰκμ, θν δ υγυθ άμνγνκαλ /εάμ ΚζδθδεάμΝ υλωεζδθδεάμν ΝΠθ ζζάθδκνσθϋ λδκν έΰκ μνεδν ιωθκ κεκη δεάμνι λδεάμ έΰζβν έκ,νσϊίί κν1γν λδζέκνβί1γ Α Α φ ; έζ δκμννένσθόμ ηί δεόμνκλ δκζόΰκμ, θν δ γθ άμνγνκλ /εάμ ΚζδθδεάμΝ λωεζδθδεάμν ένivus Scientific Director, Mediolanum

More information

StentViz Enhanced Stent Visualization

StentViz Enhanced Stent Visualization GE Healthcare StentViz Enhanced Stent Visualization Dr. Morice, Dr. Lefèvre, Dr. Hovasse, Dr. Chevalier, Dr. Louvard Institut Cardiovasculaire Paris Sud, Massy, France Assessing the deployment of stents

More information

Steven J. Yakubov, MD FACC For the CoreValve US Clinical Investigators

Steven J. Yakubov, MD FACC For the CoreValve US Clinical Investigators Long-Term Outcomes Using a Self- Expanding Bioprosthesis in Patients With Severe Aortic Stenosis Deemed Extreme Risk for Surgery: Two-Year Results From the CoreValve US Pivotal Trial Steven J. Yakubov,

More information

CONTRAST. (COntrast media and NephroToxicity following coronary Revascularization by AngioplaSTy)

CONTRAST. (COntrast media and NephroToxicity following coronary Revascularization by AngioplaSTy) Randomized clinical trial to compare the nephrotoxic effects of iso osmolar vs. low osmolar contrast medium in patients with impaired renal function undergoing PCI CONTRAST (COntrast media and NephroToxicity

More information